Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool August 30, 2011 Rex Moore	Let's See if Intuitive Surgical's Growth Is for Real Here are Intuitive Surgical's numbers, as well as a bonus look at a few other companies in its industry.
The Motley Fool March 24, 2005 Tim Beyers	Risks and Profits in Oracle's Future CEO Larry Ellison's string of successes should translate into long-term gains for shareholders. But it won't be an easy ride.
The Motley Fool September 30, 2009 Brian Orelli	Bigger Size, Lower Returns History is not on Merck and Schering's side.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool December 7, 2010 Brian Orelli	How Pfizer's New Chief Can Right the Ship Bigger is not always better.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool September 30, 2008 Brian Orelli	Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside.
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool October 13, 2004 Rich Duprey	How to Spot a Serial Acquirer Acquisitions can juice sales but can also lead to messy balance sheets. A simple test can sort them out.
The Motley Fool January 30, 2007 Brian Lawler	Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap.
The Motley Fool August 4, 2010 Matt Koppenheffer	How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale?
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool August 3, 2006 Stephen D. Simpson	Still Time to Tie Into Tyco The conglomerate's stock is undervalued, but also underperforming. Investors, take note.
BusinessWeek April 4, 2005 Steve Hamm	Larry, You Picked A Nasty Fight In taking on heavyweight SAP in the corporate applications software market, Oracle faces very long odds.
The Motley Fool January 26, 2006 Stephen D. Simpson	A Broad Base at Ingersoll-Rand A nice run in the fall took some of the cheapness out of this stock, at least relative to other conglomerates. However, Ingersoll-Rand still doesn't look overpriced.
The Motley Fool January 19, 2011 Brian Orelli	A Painfully Protracted Partner Depomed is in a bind.
The Motley Fool January 23, 2009 Robert Steyer	BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
CFO October 1, 2002 Andrew Osterland	Back to Basics? If you think new accounting rules will make acquisitions more transparent, think again.
The Motley Fool August 20, 2011 Rex Moore	2 Positive Signs for Cubist Pharmaceuticals Cubist Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool October 7, 2011 Dan Caplinger	Has CenturyLink Become the Perfect Stock? If it can build on the momentum its mergers and acquisition activity has started, CenturyLink could easily add better measures in those categories to the huge dividends it pays to its shareholders.
The Motley Fool June 20, 2005 Richard Gibbons	Think Like a Dealmaker Acquisitions can be great for investors. Here's how to identify acquisition targets before deals are announced.
The Motley Fool January 5, 2006 Tim Beyers	Dueling Fools: Oracle Bull Rebuttal All the acquisitions are adding to owner earnings. There's simply no reasonable way to call Oracle's shares expensive.
The Motley Fool November 7, 2011 Dan Caplinger	Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development.
The Motley Fool September 10, 2011 Rex Moore	Let's See If Alexion's Growth Is for Real Alexion Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value.
The Motley Fool August 14, 2008 Keith Beverly	The Best Kind of Growth Stock Be on the lookout for companies that grow organically.
InternetNews October 15, 2007 Larry Barrett	Why Oracle's Tops in Takeovers Industry watchers think BEA's days are numbered: Larry Ellison and Oracle have spent years and billions mastering the art of the takeover.
The Motley Fool August 17, 2007 Brian Lawler	The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition.
The Motley Fool August 8, 2007 Ryan Fuhrmann	Sales Grow Even as Tyco Goes Solo It looks like management is working hard to turn things around. Overall, it's still too early to tell how Tyco, Covidien, or Tyco Electronics will perform on a stand-alone basis. Investors, take note.
Chemistry World October 21, 2011 Sarah Houlton	Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool June 10, 2011 Matt Koppenheffer	5 Companies Ready to Make Acquisitions Could corporate deal-making help drive the market in the second half of the year?
The Motley Fool October 27, 2011 Eric Bleeker	Here's Where Pfizer's Finding Its Growth Let's examine where Pfizer's sales and earnings come from and how its sales abroad have changed over time.
The Motley Fool July 15, 2004 Tim Beyers	Has Larry Ellison Gone Crazy? With the PeopleSoft proposal unresolved, the Oracle chief preaches more acquisitions.
InternetNews November 8, 2004 Roy Mark	Oracle Prepared to Drop PeopleSoft Bid Oracle will drop its efforts to block PeopleSoft's defense to Oracle's hostile takeover bid if PeopleSoft's shareholders fail to tender a majority of their shares by Nov. 19, according to an Oracle letter sent to a Delaware court.
The Motley Fool February 2, 2005 Tom Taulli	Tyco's Still in Cleanup Mode Ed Breen has done a tremendous job in the Tyco turnaround. But as with all turnarounds, there's still work to be done. Its stock fell $1.63 to $34.51 upon that news. The 52-week high is $36.58.
The Motley Fool April 30, 2010 Alex Dumortier	HP Acquires Palm -- Who's Next in Tech? Watch for a boom in technology acquisitions.
The Motley Fool August 5, 2011 Rex Moore	Level 3 Communications May Be Hiding Weakness Here are Level 3 Communications' numbers, as well as a bonus look at a few other companies in its industry.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
InternetNews March 12, 2004 Michael Singer	Oracle Sees Growth From Outsourcing The company's Q3 numbers should help fuel its immediate takeover plans for PeopleSoft, as its long-term strategy shows promise.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.